Kymriah is a preparation made from your own white blood cells. It is a CD19-targeted genetically modified autologous T-cell immunotherapy indicated for the treatment of: Patients under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or has had a second or later relapse.
Price For price clarification, please contact our representative.
